TY - JOUR
T1 - Prevalence of Extrapancreatic Malignancies Among Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas
AU - Panic, Nikola
AU - Macchini, Federico
AU - Solito, Sonia
AU - Boccia, Stefania
AU - Leoncini, Emanuele
AU - Larghi, Alberto Leonardo
AU - Berretti, Debora
AU - Pevere, Sara
AU - Vadala, Salvatore
AU - Marino, Marco
AU - Zilli, Maurizio
AU - Bulajic, Milutin
PY - 2018
Y1 - 2018
N2 - Objectives: We conducted a study in order to assess the prevalence of extrapancreatic malignancies (EPMs) in a cohort of patients with intraductal papillary mucinous neoplasms (IPMNs) from northeastern Italy.
Methods: A study was conducted in hospital Santa Maria della Misericordia, Udine, Italy. Hospital records were screened in order to identify newly diagnosed IPMN cases in the period from January 1, 2009, to December 31, 2015. We searched for EPMs diagnosed previous to, synchronous to, or after the IPMN. The ratio of the observed (O) number of patients with EPMs to the expected (E) was calculated.
Results: We identified 72 EPMs in 63 (31.8%) of 198 patients included. Among them, 51 (70.8%) were diagnosed previous to, 17 (23.6%) synchronous to, and 4 (5.6%) after the IPMN. Most frequently diagnosed were colorectal (12 patients [6.1%]), breast (8 patients [6.8%, in females]), renal cell (8 patients [4.0%]), and prostate cancer (7 patients [8.6%, in males]). The O/E ratios for EPMs were significantly increased for cancer in general (3.66; 95% confidence interval [CI], 2.39-5.37), renal cell (9.62; 95% CI, 1.98-28.10), prostate (4.91; 95% CI, 1.59-11.45), and breast cancer (3.16; 95% CI, 1.03-7.37).
Conclusions: We report an increased risk of EPMs in patients with IPMN, especially for renal cell, prostate, colorectal, and breast cancer.
AB - Objectives: We conducted a study in order to assess the prevalence of extrapancreatic malignancies (EPMs) in a cohort of patients with intraductal papillary mucinous neoplasms (IPMNs) from northeastern Italy.
Methods: A study was conducted in hospital Santa Maria della Misericordia, Udine, Italy. Hospital records were screened in order to identify newly diagnosed IPMN cases in the period from January 1, 2009, to December 31, 2015. We searched for EPMs diagnosed previous to, synchronous to, or after the IPMN. The ratio of the observed (O) number of patients with EPMs to the expected (E) was calculated.
Results: We identified 72 EPMs in 63 (31.8%) of 198 patients included. Among them, 51 (70.8%) were diagnosed previous to, 17 (23.6%) synchronous to, and 4 (5.6%) after the IPMN. Most frequently diagnosed were colorectal (12 patients [6.1%]), breast (8 patients [6.8%, in females]), renal cell (8 patients [4.0%]), and prostate cancer (7 patients [8.6%, in males]). The O/E ratios for EPMs were significantly increased for cancer in general (3.66; 95% confidence interval [CI], 2.39-5.37), renal cell (9.62; 95% CI, 1.98-28.10), prostate (4.91; 95% CI, 1.59-11.45), and breast cancer (3.16; 95% CI, 1.03-7.37).
Conclusions: We report an increased risk of EPMs in patients with IPMN, especially for renal cell, prostate, colorectal, and breast cancer.
KW - Breast Neoplasms
KW - Carcinoma
KW - Cohort Studies
KW - Colorectal Neoplasms
KW - Comorbidity
KW - Mucinous
KW - Pancreatic Neoplasms
KW - Prostatic Neoplasms
KW - Breast Neoplasms
KW - Carcinoma
KW - Cohort Studies
KW - Colorectal Neoplasms
KW - Comorbidity
KW - Mucinous
KW - Pancreatic Neoplasms
KW - Prostatic Neoplasms
UR - http://hdl.handle.net/10807/148344
U2 - 10.1097/MPA.0000000000001072
DO - 10.1097/MPA.0000000000001072
M3 - Article
SN - 1536-4828
VL - 47
SP - 721
EP - 724
JO - Pancreas
JF - Pancreas
ER -